MAPK Signaling
Targets for MAPK Signaling
- ERK(85)
- MEK1/2(74)
- NKCC(5)
- MNK(6)
- PKA(56)
- p38(103)
- Rac(2)
- Raf(76)
- RasGAP (Ras- P21)(1)
- JNK(66)
- cAMP(33)
- Protein Kinase G(2)
- RSK(33)
- Other(759)
- MAPKAPK(1)
- MKK(2)
- KLF(3)
- MAP3K(22)
- MAP4K(21)
- MAPKAPK2 (MK2)(9)
- Mixed Lineage Kinase(9)
Products for MAPK Signaling
- Cat.No. Product Name Information
- GC13142 RWJ 67657 orally active inhibitor of the MAP kinases p38α and p38β
- GC18273 SB 202190 (hydrochloride) SB 202190 is a potent, selective, and cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively.
- GC16019 SB 202474 a negative control in studies of p38 inhibition
- GC13001 SB 203580 hydrochloride Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively.
- GC10054 SB 239063 A selective p38 MAPK inhibitor
- GC37595 SB 242235 SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC50 of 1.0 μM in primary human chondrocytes.
- GC11922 SB 706504 p38 MAPK inhibitor
- GC13968 SB202190 (FHPI) SB202190 (FHPI) is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively.
- GC11890 SB590885 Potent B-Raf inhibitor
-
GC16001
SCH772984
A selective inhibitor of ERK1/2
-
GC14647
SCH772984 HCl
ERK1/2 inhibitor
-
GC15044
SCH772984 TFA
ERK1/2 inhibitor
- GC19325 SD 0006 SD-06 is a p38 MAP kinase inhibitor; inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po).IC50 value: 170 nM.
- GC14982 SD 169 selective ATP competitive inhibitor of the MAP kinases p38α and p38β
- GC12124 Selonsertib (GS-4997) Selonsertib (GS-4997) (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.
- GC38653 Selumetinib sulfate Selumetinib (AZD6244) is selective, non-ATP-competitive oral?MEK1/2?inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
- GC39815 Semapimod tetrahydrochloride Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6.
- GC10005 SEP-0372814 A PDE10A inhibitor
- GC33229 SJFα SJFα is a 13-atom linker PROTAC based on von Hippel-Lindau ligand. SJFα degrades p38α with a DC50 of 7.16nM, but is far less effective at degrading p38δ (DC50=299nM) and does not degrade the other p38 isoforms (β and γ) at concentrations up to 2.5μM.
- GC33238 SJFδ SJFδ is a 10-atom linker PROTAC based on von Hippel-Lindau ligand. SJFδ degrades p38δ with a DC50 of 46.17nM, but does not degrade p38α, p38β, or p38γ.
- GC30646 Skatole(3-Methylindole) Skatole(3-Methylindole) is produced by intestinal bacteria, regulates intestinal epithelial cellular functions through activating aryl hydrocarbon receptors and p38.
- GC13578 Skepinone-L An inhibitor of p38 MAPK
- GC17725 SKF 86002 dihydrochloride p38 MAP kinase inhibitor
- GC37646 SKF-86002 SKF-86002 is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities.
- GC18532 Skyrin Skyrin is a fungal metabolite characterized by a bisanthraquinone structure.
- GC16313 SL 0101-1 ribosomal S6 kinase inhibitor
- GC15359 SL-327 Selective MEK1/2 inhibitor
- GC32937 SLV-2436 (SEL201-88) SLV-2436 (SEL201-88) is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50s of 10.8 nM and 5.4 nM, respectively.
- GC62675 SM1-71 SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.
- GC17425 Sodium Tauroursodeoxycholate (TUDC) Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
-
GC17369
Sorafenib
Sorafenib acts as a multi-kinase inhibitor, targeting Raf-1 and B-Raf with IC50 values of 6 nM and 22 nM, respectively.
- GC37664 Sorafenib (D3) An internal standard for the quantification of sorafenib
- GC37665 Sorafenib (D4) Sorafenib (D4) (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
- GC44917 Sorafenib N-oxide Sorafenib N-oxide is an active metabolite of sorafenib, an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases.
- GC10428 Sp-5,6-dichloro-cBIMPS (sodium salt) PKA activator
- GC44920 Sp-8-bromo-Cyclic AMPS (sodium salt) Sp-8-bromo-cyclic AMPS (Sp-8-bromo-cAMPS) is a cell-permeable, cAMP analog that combines an exocyclic sulfur substitution in the axial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP.
- GC61747 Sp-cAMPS Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II.
-
GC16652
SR 3576
JNK3 inhibitor, potent and selective
- GC30864 SR-3306 SR-3306 is a selective, potent, highly brain penetrant JNK inhibitor.
- GC64287 SR15006 SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells).
- GC50406 st-Ht31 Inhibits PKA/AKAP interactions; cell permeable
- GC50407 st-Ht31 P Negative control for st-Ht31
- GC50501 STAD 2 AKAP disruptor; selectively binds PKA-RII and blocks its interaction with AKAP; cell permeable
-
GC15299
Staurosporine(CGP 41251)
A potent inhibitor of protein kinase C
- GC11542 SU 3327 JNK inhibitor
-
GC13825
TA 01
CK1ε, CK1δ,and p38α inhibitor
- GC11635 TA 02 p38 MAPK inhibitor
- GC16543 TAK-715 A p38 MAPK inhibitor
- GC10209 TAK-733 MEK allosteric site inhibitor
- GC62497 TAK1-IN-2 TAK1-IN-2 is a potent and selective TAK1 inhibitor, with an IC50> of 2 nM.
-
GC69984
TAK1-IN-4
TAK1-IN-4 (Compound 14) is a TAK1 inhibitor.
- GC49700 Takeda-6d
- GC32687 Takinib A TAK1 inhibitor
- GC34072 Talmapimod (SCIO-469) Talmapimod (SCIO-469) (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. Talmapimod (SCIO-469) shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs.
- GC25982 Tanzisertib(CC-930) Tanzisertib (CC-930, JNK-930, JNKI-1) is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively.
- GC34181 Tauroursodeoxycholate (TUDCA) Tauroursodeoxycholate (TUDCA) (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate (TUDCA) significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate (TUDCA) also inhibits ERK.
- GC34831 Tauroursodeoxycholate dihydrate Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
- GC34057 TBHQ (tert-Butylhydroquinone) TBHQ (tert-Butylhydroquinone) (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2. TBHQ (tert-Butylhydroquinone) (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma.
- GC14853 TC ASK 10 ASK1 inhibitor
- GC34140 TC13172 TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC50 value of 2 nM for HT-29 cells.
- GC11488 TCS JNK 5a JNK2 and JNK3 inhibitor
- GC17282 TCS JNK 6o TCS JNK 6o (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively.
- GC39074 Tenuifoliside A Tenuifoliside A is isolated from Polygala tenuifolia, has anti-apoptotic and antidepressant-like effects.
-
GC41573
Theaflavin 3,3'-digallate
Theaflavin-3,3'-digallate (TFDG) is a major polyphenol found in black tea with diverse biological activities.
- GC68350 Tinlorafenib
- GC50295 TL4-12 Potent MAP4K2 (GCK) inhibitor
- GC31647 Tomatidine Tomatidine acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling.
- GC45064 Tomatidine (hydrochloride) Tomatidine is a steroidal alkaloid that has been found in the skins and leaves of tomatoes.
- GC19131 Tomivosertib eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms.
- GC45067 Tpl2 Kinase Inhibitor Tpl2 Kinase Inhibitor (Compound 1) is a potent and selective Tpl2 (COT kinase, MAP3K8) inhibitor, plays an important role in the regulation of the inflammatory response and the progression of some cancers.
- GC49150 Tpl2 Kinase Inhibitor (hydrochloride) A Tpl2 inhibitor
-
GC70053
Trametiglue
Trametiglue is a derivative of Trametinib that binds to KSR-MEK and RAF-MEK with unprecedented potency and selectivity through a unique interface interaction.
-
GC13508
Trametinib (GSK1120212)
An inhibitor of MEK1 and MEK2
- GC15260 Trametinib DMSO solvate
- GC30162 trans-Zeatin A cytokinin plant growth regulator
-
GC45099
U-0126
A MEK inhibitor
- GC15061 U0124 Inactive analog of U0126(MEK-1/2 inhibitor), used as a negative control
- GC12807 U0126-EtOH U0126-EtOH-EtOH (U0126 has potent inhibition on MEK1 and MEK2 with IC50s of 72 nM and 58 nM, respectively
- GC16678 UCN-02 protein kinase C inhibitor
- GC11422 Ulixertinib (hydrochloride) reversible ERK1/2 inhibitor
- GC19366 UM-164 UM-164 is a highly potent inhibitor of c-Src with a Kd of 2.7 nM.
-
GC15004
URMC-099
URMC-099, as a 7‐azaindole‐based MLK3 inhibitor with IC50 of 14 nM, could specifically affect specific Aβ species engaged in disease pathobiology[1].
- GC38679 Urolithin B A metabolite of ellagic acid
- GC17818 Vacquinol-1 Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates MAPK pathways. Vacquinol-1 specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model. Vacquinol-1 also induces apoptosis in hepatocellular carcinoma (HCC)cell.
-
GC13412
Vemurafenib (PLX4032, RG7204)
An inhibitor of mutant V600E and wild type B-Raf
- GC17031 VRT752271 VRT752271 (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. VRT752271 (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.
- GC13115 VX-11e A selective ERK inhibitor
- GC17508 VX-702 P38α MAPK inhibitor,highly selective and ATP-competitive
- GC12926 VX-745 VX-745 (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC50 for p38α of 10 nM and for p38β of 220 nM.
- GC30857 Warangalone (Scandenolone) Warangalone (Scandenolone) is an anti-malarial compound which can inhibit the growth of both strains of parasite 3D7 (chloroquine sensitive) and K1 (chloroquine resistant) with IC50s of 4.8 μg/mL and 3.7 μg/mL, respectively.
- GC38053 WHI-P258 A negative control for JAK3 inhibition
- GC12691 XMD17-109 A selective ERK5 inhibitor
- GC11076 XMD8-92 A selective ERK5 inhibitor
- GC16169 XRP44X Ras-Net (Elk-3) pathway inhibitor
- GC62146 XST-14 XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects.
- GC63264 Zapnometinib Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM.
- GC13286 ZM336372 C-Raf inhibitor, potent and selective
- GC63425 Zunsemetinib Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.